SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Speculating in Takeover Targets
ULBI 4.230+2.4%12:08 PM EDT

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: richardred7/3/2007 12:07:12 AM
  Read Replies (1) of 7159
 
Santarus Shares Rise on Upgrade
Monday July 2, 12:24 pm ET
Santarus Shares Rise After Analyst Upgrades Citing Stock-Price Pullback, Buyout Possibility

NEW YORK (AP) -- Santarus Inc. shares rose Monday after a Susquehanna Financial Group analyst upgraded the drug developer, saying a recent decline in share price has made the company a more attractive buyout target.

Angela Larson raised her rating to "Neutral" from "Negative."

Santarus shares are down 34 percent so far this year. and have steadily declined since the company announced a larger-than-expected first-quarter loss on May 2. On June 22, shares hit a 52-week low of $4.82.

Larson said Santarus' sole product -- the acid reflux drug Zegerid -- does not stand out in the competitive heartburn market, and the company is not developing new products.

But the analyst said the stock price could make Santarus attractive to a buyer. However, she added "Our lack of confidence in the fundamental operations for the company limits our enthusiasm for significant upside from current levels."

Shares of Santarus rose 33 cents, or 6.4 percent, to $5.50.

Questions or comments about this story should be directed to the Financial News desk of The Associated Press at (212) 621-7190.
biz.yahoo.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext